Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

590
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
590
Cholera01:25

Cholera

142
Cholera is an acute gastrointestinal disease caused by the Gram-negative bacterium Vibrio cholerae. It is transmitted primarily via the fecal-oral route through the ingestion of contaminated water or food.Vibrio cholerae is a motile, Gram-negative bacterium of the family Vibrionaceae, primarily associated with waterborne outbreaks in areas with inadequate sanitation. Although over 200 serogroups of V. cholerae exist, only O1 and O139 are responsible for epidemic cholera. The O1 serogroup,...
142
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

844
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
844
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

1.0K
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
1.0K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

999
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
999
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

700
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
700

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of oral contrast use in CT imaging for acute appendicitis on time to surgery: a single-center before-after cohort study.

Annals of medicine and surgery (2012)·2026
Same author

Outcomes of deprescribing for people with life-limiting conditions: A systematic review.

Palliative medicine·2026
Same author

Comparison of levels of satisfaction and rates of adverse events in different anatomical injection sites in outbound travelers: a randomized controlled trial.

Tropical diseases, travel medicine and vaccines·2026
Same author

Oral iron supplements for children in malaria-endemic areas.

The Cochrane database of systematic reviews·2026
Same author

Carbapenem-resistant Enterobacterales (CRE) acquisition and molecular characterization following colistin monotherapy and colistin-meropenem combination therapy: findings from the AIDA randomized trial.

Antimicrobial resistance and infection control·2025
Same author

A Host-Protein Test for Differentiating Bacterial From Viral Infection: Diagnostic Accuracy in Elderly Patients.

Journal of the American College of Emergency Physicians open·2025

Related Experiment Video

Updated: Apr 28, 2026

Determination of Tolerable Fatty Acids and Cholera Toxin Concentrations Using Human Intestinal Epithelial Cells and BALB/c Mouse Macrophages
09:39

Determination of Tolerable Fatty Acids and Cholera Toxin Concentrations Using Human Intestinal Epithelial Cells and BALB/c Mouse Macrophages

Published on: May 30, 2013

9.2K

Antimicrobial drugs for treating cholera.

Ya'ara Leibovici-Weissman1, Ami Neuberger, Roni Bitterman

  • 1Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 49100.

The Cochrane Database of Systematic Reviews
|June 20, 2014
PubMed
Summary

Antimicrobial drugs significantly reduce cholera symptoms, shortening diarrhea duration and decreasing fluid loss. These treatments offer benefits for both severe and non-severe cholera cases, with azithromycin and tetracycline showing potential advantages.

More Related Videos

Laboratory Techniques Used to Maintain and Differentiate Biotypes of Vibrio cholerae Clinical and Environmental Isolates
07:58

Laboratory Techniques Used to Maintain and Differentiate Biotypes of Vibrio cholerae Clinical and Environmental Isolates

Published on: May 30, 2017

10.4K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K

Related Experiment Videos

Last Updated: Apr 28, 2026

Determination of Tolerable Fatty Acids and Cholera Toxin Concentrations Using Human Intestinal Epithelial Cells and BALB/c Mouse Macrophages
09:39

Determination of Tolerable Fatty Acids and Cholera Toxin Concentrations Using Human Intestinal Epithelial Cells and BALB/c Mouse Macrophages

Published on: May 30, 2013

9.2K
Laboratory Techniques Used to Maintain and Differentiate Biotypes of Vibrio cholerae Clinical and Environmental Isolates
07:58

Laboratory Techniques Used to Maintain and Differentiate Biotypes of Vibrio cholerae Clinical and Environmental Isolates

Published on: May 30, 2017

10.4K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Clinical Medicine

Background:

  • Cholera, caused by Vibrio cholerae, is a severe diarrheal disease leading to rapid dehydration and death.
  • Early diagnosis and rehydration are crucial for cholera management.
  • This review assesses the added benefits of antimicrobial drugs in cholera treatment.

Purpose of the Study:

  • To quantify the effectiveness of antimicrobial treatment in cholera patients.
  • To compare different classes of antimicrobials and dosing schedules for cholera.

Main Methods:

  • Systematic review and meta-analysis of 39 randomized and quasi-randomized controlled trials.
  • Inclusion of trials comparing antimicrobials to placebo/no treatment, or different antimicrobials/dosing schedules.
  • Primary outcomes included diarrhea duration and stool volume; GRADE approach used for quality assessment.

Main Results:

  • Antimicrobials reduced diarrhea duration by ~1.5 days and stool volume by 50% compared to placebo.
  • Treatment decreased rehydration fluid requirements by 40% and shortened Vibrio excretion by ~3 days.
  • Azithromycin and tetracycline showed potential advantages over other antimicrobials.

Conclusions:

  • Antimicrobial therapy significantly improves clinical and microbiological outcomes in cholera.
  • Benefits are consistent across patients with varying dehydration severity.
  • Azithromycin and tetracycline may be preferred choices for cholera treatment.